{"id":66703,"date":"2026-05-29T14:50:27","date_gmt":"2026-05-29T06:50:27","guid":{"rendered":"https:\/\/flcube.com\/?p=66703"},"modified":"2026-05-29T14:50:28","modified_gmt":"2026-05-29T06:50:28","slug":"hengrui-pharmaceuticals-receives-nmpa-approval-to-study-shr-1819-in-pediatric-atopic-dermatitis-challenging-sanofis-dupilumab","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66703","title":{"rendered":"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#8217;s Dupilumab"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced it has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a clinical study of its <strong>SHR-1819<\/strong> in <strong>atopic dermatitis<\/strong> for children aged <strong>6 months to 5 years<\/strong>. SHR-1819 is a <strong>recombinant humanized monoclonal antibody<\/strong> targeting <strong>human IL-4R\u03b1<\/strong>, designed to simultaneously block <strong>IL-4 and IL-13 signaling<\/strong> pathways.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-study-details\" class=\"wp-block-heading\">Regulatory Milestone &amp; Study Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical study authorization<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Children aged 6 months to 5 years<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Atopic dermatitis<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Recombinant humanized monoclonal antibody<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>IL-4R\u03b1 (dual blockade of IL-4 and IL-13)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-pipeline\" class=\"wp-block-heading\">Drug Profile &amp; Development Pipeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> Dual inhibition of IL-4 and IL-13 signaling through IL-4R\u03b1 targeting<\/li>\n\n\n\n<li><strong>Therapeutic Area:<\/strong> Type 2 inflammatory diseases<\/li>\n\n\n\n<li><strong>Current Indications in Development:<\/strong><\/li>\n\n\n\n<li>Atopic dermatitis (multiple age groups)<\/li>\n\n\n\n<li>Prurigo nodularis<\/li>\n\n\n\n<li>Chronic spontaneous urticaria<\/li>\n\n\n\n<li>Allergic rhinitis<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Multiple programs already in Phase II\/III clinical development<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Target<\/th><th>China Approval Status<\/th><th>Pediatric Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Dupilumab<\/strong><\/td><td>Sanofi\/Regeneron<\/td><td>IL-4R\u03b1<\/td><td><strong>Approved<\/strong> for atopic dermatitis<\/td><td>Approved for children \u22656 months<\/td><\/tr><tr><td><strong>SHR-1819<\/strong><\/td><td>Hengrui Pharmaceuticals<\/td><td>IL-4R\u03b1<\/td><td><strong>Clinical study approved<\/strong><\/td><td>Study authorized for 6 months-5 years<\/td><\/tr><tr><td><strong>Tralokinumab<\/strong><\/td><td>Leo Pharma<\/td><td>IL-13<\/td><td>Not approved in China<\/td><td>Limited pediatric data<\/td><\/tr><tr><td><strong>Nemolizumab<\/strong><\/td><td>Chugai\/Roche<\/td><td>IL-31RA<\/td><td>Not approved in China<\/td><td>Phase III in adolescents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<h3 id=\"h-for-hengrui-pharmaceuticals\" class=\"wp-block-heading\">For Hengrui Pharmaceuticals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Domestic Advantage:<\/strong> Potential to become first Chinese-developed IL-4R\u03b1 inhibitor approved for pediatric atopic dermatitis<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses significant unmet need in China&#8217;s large pediatric atopic dermatitis population<\/li>\n\n\n\n<li><strong>Pricing Leverage:<\/strong> Local manufacturing could enable competitive pricing against imported biologics<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success would validate Hengrui&#8217;s broader type 2 inflammation platform<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-atopic-dermatitis-market-dynamics\" class=\"wp-block-heading\">China Atopic Dermatitis Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Disease Burden:<\/strong> Estimated 20-30 million atopic dermatitis patients in China, with substantial pediatric population<\/li>\n\n\n\n<li><strong>Limited Treatment Options:<\/strong> Few biologics currently approved for young children<\/li>\n\n\n\n<li><strong>Import Dependency:<\/strong> Current market dominated by foreign-developed therapies like dupilumab<\/li>\n\n\n\n<li><strong>Healthcare Policy Support:<\/strong> Government initiatives favor domestic innovative biologics for chronic conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-commercial-outlook\" class=\"wp-block-heading\">Development Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Stage:<\/strong> NMPA approval for pediatric clinical study (6 months-5 years)<\/li>\n\n\n\n<li><strong>Adult Programs:<\/strong> Likely more advanced given multiple Phase II\/III programs across indications<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Potential for accelerated approval based on adult data extrapolation to pediatric population<\/li>\n\n\n\n<li><strong>Market Entry:<\/strong> Estimated 2028-2029 timeline if clinical development progresses successfully<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential for SHR-1819. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260529_DPYC.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260529_DPYC.\"><\/object><a id=\"wp-block-file--media-db8e4966-fdc3-448b-a380-227588b903b4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260529_DPYC.pdf\">600276_20260529_DPYC<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260529_DPYC.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-db8e4966-fdc3-448b-a380-227588b903b4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,2586,68,852],"class_list":["post-66703","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-pediatric-drugs","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#039;s Dupilumab - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study of its SHR-1819 in atopic dermatitis for children aged 6 months to 5 years. SHR-1819 is a recombinant humanized monoclonal antibody targeting human IL-4R\u03b1, designed to simultaneously block IL-4 and IL-13 signaling pathways.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66703\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#039;s Dupilumab\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study of its SHR-1819 in atopic dermatitis for children aged 6 months to 5 years. SHR-1819 is a recombinant humanized monoclonal antibody targeting human IL-4R\u03b1, designed to simultaneously block IL-4 and IL-13 signaling pathways.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66703\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T06:50:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T06:50:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66703#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66703\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#8217;s Dupilumab\",\"datePublished\":\"2026-05-29T06:50:27+00:00\",\"dateModified\":\"2026-05-29T06:50:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66703\"},\"wordCount\":430,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"Pediatric drugs\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66703#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66703\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66703\",\"name\":\"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi's Dupilumab - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T06:50:27+00:00\",\"dateModified\":\"2026-05-29T06:50:28+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study of its SHR-1819 in atopic dermatitis for children aged 6 months to 5 years. SHR-1819 is a recombinant humanized monoclonal antibody targeting human IL-4R\u03b1, designed to simultaneously block IL-4 and IL-13 signaling pathways.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66703#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66703\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66703#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#8217;s Dupilumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi's Dupilumab - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study of its SHR-1819 in atopic dermatitis for children aged 6 months to 5 years. SHR-1819 is a recombinant humanized monoclonal antibody targeting human IL-4R\u03b1, designed to simultaneously block IL-4 and IL-13 signaling pathways.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66703","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi's Dupilumab","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study of its SHR-1819 in atopic dermatitis for children aged 6 months to 5 years. SHR-1819 is a recombinant humanized monoclonal antibody targeting human IL-4R\u03b1, designed to simultaneously block IL-4 and IL-13 signaling pathways.","og_url":"https:\/\/flcube.com\/?p=66703","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T06:50:27+00:00","article_modified_time":"2026-05-29T06:50:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66703#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66703"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#8217;s Dupilumab","datePublished":"2026-05-29T06:50:27+00:00","dateModified":"2026-05-29T06:50:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66703"},"wordCount":430,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","Pediatric drugs","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66703#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66703","url":"https:\/\/flcube.com\/?p=66703","name":"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi's Dupilumab - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T06:50:27+00:00","dateModified":"2026-05-29T06:50:28+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study of its SHR-1819 in atopic dermatitis for children aged 6 months to 5 years. SHR-1819 is a recombinant humanized monoclonal antibody targeting human IL-4R\u03b1, designed to simultaneously block IL-4 and IL-13 signaling pathways.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66703#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66703"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66703#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi&#8217;s Dupilumab"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66703"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66703\/revisions"}],"predecessor-version":[{"id":66705,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66703\/revisions\/66705"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}